International Longevity Centre

Kevés kutatás található a fizikai munkavállalók egészségmagatartásáról, egészségfejlesztéséről. A szerzők esettanulmányának célja, hogy bemutassa e munkavállalók munkahelyi egészségfejlesztésének kihívásait és lehetőségeit egy magyarországi gyártó vállalat példáján keresztül. A kutatás keretében hét vezető beosztású munkatárssal folytattak félig strukturált mélyinterjút, amelyek során feltárták az akadályozó tényezőket, valamint az egészségfejlesztési kezdeményezések jövőbeli lehetőségeit. A kvalitatív adatelemzés hat fő területet azonosított: 1. egészségfejlesztés fontossága, vezetők elköteleződése, 2. fizikai munkavállalók egészségi állapota, 3. a dolgozók egészségmagatartása, egészségtudatosság, 4. a munka jellegéhez kapcsolódó specialitások, 5. kommunikáció, 6. priorizált egészségfejlesztési területek. Az eredmények alapján konkrét javaslatokat fogalmaztak meg a vállalat számára, amelyek a HAPA-modell két fázisára, a dolgozók aktív bevonására és a műszakos munkavégzésre vonatkoztak. A tanulmány öt, más vállalatok számára is megfontolandó, a vállalatnál bevált, alkalmazott „jó gyakorlatot” is sorra vesz. A cikk hozzájárul a munkahelyi egészségfejlesztés irodalmához, különös tekintettel a fizikai munkát végzők speciális igényeire, kihívásaira és lehetőségeire.

<title>Abstract</title> <bold>Background</bold> Severe and critical COVID-19 are characterized by immune dysregulation, systemic inflammation, endothelial injury, and high short-term mortality. While antiviral therapy and corticosteroids have improved outcomes, therapeutic options that directly modulate the hyperinflammatory state remain limited. Intravenous mesenchymal stromal cells (MSCs) have emerged as a regenerative medicine strategy intended to attenuate inflammation and improve clinical outcomes. <bold>Objective</bold> To evaluate randomized placebo-controlled clinical trial evidence for intravenous MSC therapy in adults with severe and critical COVID-19, with emphasis on short-term mortality and systemic inflammatory biomarker outcomes. <bold>Methods</bold> A systematic review was conducted to identify randomized placebo-controlled clinical trials evaluating intravenous MSC therapy in severe or critical COVID-19. The primary endpoint was short-term all-cause mortality. Secondary outcomes included clinical severity measures and systemic inflammatory biomarkers, including C-reactive protein (CRP) and interleukin-6 (IL-6). When trials did not provide numeric endpoint values in tables, values were extracted from published figures as estimated mean and dispersion measures. Outcomes were synthesized under a random effects framework. <bold>Results</bold> Four randomized placebo-controlled trials met criteria for quantitative synthesis. Across trials, MSC therapy demonstrated a favorable direction of effect for short-term mortality compared with placebo. MSC therapy was consistently associated with greater reductions in CRP and IL-6 compared with placebo control arms. No clear signal of increased serious treatment-related adverse events was identified. <bold>Conclusion</bold> Randomized placebo-controlled clinical trial evidence suggests intravenous MSC therapy may reduce systemic inflammation and favorably influence short-term outcomes in severe and critical COVID-19. Larger randomized trials with standardized outcome reporting are needed to further define efficacy, durability, and optimal patient selection.

Rapid advances in microbiome science have sparked clinical and commercial enthusiasm for interventions, yet translation into practice risks outpacing both mechanistic understanding and the infrastructure required for safe adoption. To outline a coordinated research, clinical, social, and policy agenda for advancing safe, effective, and equitable microbiome-based interventions. We convened an interdisciplinary Royal Society-funded expert workshop (Leeds, UK, October 2024) with international leaders in microbiome science, clinical trials, regulation, and social science. Thematic analysis of workshop discussions and written contributions identified priority domains for translation. Three intersecting priorities emerged: scientific credibility, practical viability, and stakeholder engagement. Scientific credibility demands investment in multiomic and strain-level characterization of host-microbiome interactions on a large scale, benchmarking of clinical and microbiological endpoints, and harmonization of trial conduct and reporting. Clinical adoption requires fit-for-purpose regulation, diversified investment to address funding bottlenecks, and coordinated capacity building. Meaningful stakeholder engagement with clinicians, patients, policymakers, and the public is essential to foster confidence, develop clinically relevant research questions, and ensure equitable implementation of any new technology. To realize the clinical impact of microbiome interventions, sustained collaboration across disciplines is essential. This review offers a translational roadmap and actionable priorities to accelerate safe, effective, and equitable microbiome-based interventions-ensuring the field fulfils its clinical potential and delivers real-world impact.

Abstract Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition with increasing prevalence, often associated with oxidative stress, mitochondrial dysfunction, and neuroinflammation. This review explores the role of neuronutritions and polyphenols as potential therapeutic strategies for managing ASD. Neuronutrition focuses on bioactive dietary compounds that activate vitagenes, which are crucial genes involved in cellular stress response. Nutrients such as sulforaphane, acetyl-L-carnitine, and omega-3 fatty acids have shown promise in improving oxidative stress and mitochondrial function in ASD patients. Polyphenols, including resveratrol, epigallocatechin-3-gallate (EGCG), luteolin, and curcumin, have demonstrated neuroprotective effects by reducing neuroinflammation and enhancing antioxidant defense. Both neuronutrients and polyphenols leverage hormesis, which is a biological response to mild stressors, to improve cellular resilience and brain health. Clinical studies support their potential in alleviating ASD symptoms, suggesting that targeted dietary interventions could complement conventional treatments. Further research is required to understand the long-term efficacy and mechanisms of these interventions for ASD management.

Genomic data has become increasingly accessible to the general public with the advent of companies offering whole genome sequencing at a relatively low cost. However, their reports are not verifiable due to a lack of crucial details and transparency: polygenic risk scores do not always mention all the polymorphisms involved. Simultaneously, tackling the manual investigation and interpretation of data proves challenging for individuals lacking a background in genetics. Currently, there is no open-source or commercial solution that provides comprehensive longevity reports surpassing a limited number of polymorphisms. Additionally, there are no ready-made, out-of-the-box solutions available that require minimal expertise to generate reports independently. To address these issues, we have developed the Just-DNA-Seq open-source genomic platform. Just-DNA-Seq aims to provide a user-friendly solution to genome annotation by allowing users to upload their own VCF files and receive annotations of their genetic variants and polygenic risk scores related to longevity. We also created GeneticsGenie custom GPT that can answer genetics questions based on our modules. With the Just-DNA-Seq platform, we want to provide full information regarding the genetics of long life: disease-predisposing variants, that can reduce lifespan and manifest at different age (cardiovascular, oncological, neurodegenerative diseases, etc.), pro-longevity variants and longevity drug pharmacokinetics. In this research article, we will discuss the features and capabilities of Just-DNA-Seq, and how it can benefit individuals looking to understand and improve their health. It's crucial to note that the Just-DNA-Seq platform is exclusively intended for scientific and informational purposes and is not suitable for medical applications.

Chemotherapy Related Cognitive Impairment (CRCI), also called chemobrain, diminishes cancer patient's life quality. Breast cancer (BC) patients have been described to be importantly affected, however, the mechanism leading to CRCI has not been fully elucidated. Recent research proposes microglia as the main architect of CRCI, thus dysregulations in these cells could trigger CRCI. The aim of this research was to evaluate the effects of two drugs commonly used against breast cancer, cyclophosphamide (CTX) and epirubicin (EPI), on the microglia cell line SIM-A9, using the BC cell line, 4T1, as a control. Our results show that CTX and EPI decrease microglia-cell viability and increase cell death on a concentration-dependent manner, being 5 and 2 times more cytotoxic to microglia cell line than to breast cancer 4T1cells, respectively. Both chemotherapies induce cell cycle arrest and a significant increase in p53, p16 and γ-H2AX in breast cancer and microglia cells. Furthermore, mitochondrial membrane potential (ΔΨm) diminishes as cell death increases, and both chemotherapies induce reactive oxygen species (ROS) production on SIM-A9 and 4T1. Moreover, caspase activation increases with treatments and its pharmacological blockade inhibits CTX and EPI induced-cell death. Finally, low concentrations of CTX and EPI induce γ-H2AX, and EPI induces cytokine release, NO production and Iba-1 overexpression. These findings indicate that microglia cells are more sensitive to CTX and EPI than BC cells and undergo DNA damage and cell cycle arrest at very low concentrations, moreover EPI induces microglia activation and a pro-inflammatory profile.

Time-Restricted Eating is an eating pattern based on the circadian rhythm which limits daily food intake (usually to ≤12 h/day), unique in that no overt restriction is imposed on the quality, nor quantity, of food intake. This paper aimed to examine the effects of two patterns of TRE, traditional TRE, and Ramadan fasting, on two markers of circadian rhythm, cortisol and melatonin. PubMed and Web of Science were searched up to December 2020 for studies examining the effects of time restricted eating on cortisol and melatonin. Fourteen studies met our inclusion criteria. All Ramadan papers found statistically significant decrease in melatonin (p < 0.05) during Ramadan. Two out of the three Ramadan papers noted an abolishing of the circadian rhythm of cortisol (p < 0.05). The non-Ramadan TRE papers did not examine melatonin, and cortisol changes were mixed. In studies comparing TRE to control diets, Stratton et al. found increased cortisol levels in the non-TRE fasting group (p = 0.0018) and McAllister et al. noted no difference. Dinner-skipping resulted in significantly reduced evening cortisol and non-significantly raised morning cortisol. Conversely, breakfast skipping resulted in significantly reduced morning cortisol. This blunting indicates a dysfunctional HPA axis, and may be associated with poor cardio-metabolic outcomes. There is a paucity of research examining the effects of TRE on cortisol and melatonin. The contrasting effect of dinner and breakfast-skipping should be further examined to ascertain whether timing the feeding window indeed has an impact on circadian rhythmicity.